Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Heatmap
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
X
XBI
State Street SPDR S&P Biotech ETF
136.2
0
USD
+9917.65%
Sektor:
Finanzen
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
+9917.65%
Monatliche Änderung
+5.17%
6 month change
+11.88%
Jahresänderung
+23.67%
Vorheriger Schlusskurs
1.3
6
Open
136.4
8
Tief
136.1
5
High
136.7
3
Volumen
649
Märkte
US ETFs
XBI
Vollständige Grafik anzeigen
Full chart
Übersicht
Alle Anlagen
Heatmap
Top-Positionen
Market Value
Shares
Weight %
F
FOLD
Amicus Therapeutics Inc
117.0 M
8.2 M
1.5%
PRAX
Praxis Precision Medicines Inc
109.2 M
370.4 K
1.4%
TVTX
Travere Therapeutics Inc
107.7 M
2.8 M
1.4%
BMRN
BioMarin Pharmaceutical Inc
107.2 M
1.8 M
1.4%
HALO
Halozyme Therapeutics Inc
104.1 M
1.5 M
1.3%
ROIV
Roivant Sciences Ltd
103.9 M
4.8 M
1.3%
EXEL
Exelixis Inc
103.4 M
2.4 M
1.3%
REGN
Regeneron Pharmaceuticals Inc
103.0 M
133.4 K
1.3%
PCVX
Vaxcyte Inc
102.8 M
2.2 M
1.3%
MDGL
Madrigal Pharmaceuticals Inc
102.1 M
175.4 K
1.3%
CYTK
Cytokinetics Inc
102.1 M
1.6 M
1.3%
BBIO
Bridgebio Pharma Inc
102.0 M
1.3 M
1.3%
AMGN
Amgen Inc
100.6 M
307.3 K
1.3%
INCY
Incyte Corp
100.6 M
1.0 M
1.3%
KRYS
Krystal Biotech Inc
99.7 M
404.2 K
1.3%
PTCT
PTC Therapeutics Inc
99.3 M
1.3 M
1.3%
RVMD
Revolution Medicines Inc
99.1 M
1.2 M
1.3%
RYTM
Rhythm Pharmaceuticals Inc
99.0 M
925.0 K
1.3%
VRTX
Vertex Pharmaceuticals Inc
98.8 M
217.9 K
1.3%
MRNA
Moderna Inc
98.4 M
3.3 M
1.3%
1
2
3
4
5
6
7
8
Nachrichten
First Quarter Earnings: Sharpening Sector Divergence
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
3 Reasons To Stick With Growth Stocks In Rotating Markets
Seeking Innovation Beyond Tech? Insight On Healthcare Stocks
Biotech Investors Are Tuning Out the MAHA Chaos
Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)
Capricor: B. Riley bestätigt Kursziel von 63 US-Dollar angesichts von FDA-Fortschritten
FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint
Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)
Mizuho senkt Kursziel für Immunocore wegen Umsatzprognose auf 34 Dollar
What's The Dominant Trend In Earnings: AI Or Geopolitics?